MOUNTAIN VIEW, Calif.
, April 28, 2011
/PRNewswire/ -- Xlumena, a privately held provider of innovative technology for the interventional endoscopist and endoscopic surgeon, today announced it has successfully closed its Series B financing.
The current round of financing was led by new investor, Aperture Venture Partners, LLC and joined by Western Technology Investment. In conjunction with the financing, Eric Sillman of Aperture Venture Partners and Avi Kometz, MD of Ascent Biomedical Ventures will join Xlumena's Board of Directors. "Xlumena has tremendous potential to deliver innovative devices to the emerging field of interventional and therapeutic endoscopy. We are excited to lead the Series B financing and to begin collaborating with Xlumena's team to expand the impact of their novel technologies," stated Eric Sillman, General Partner of Aperture Venture Partners.
Also participating in the current round of financing were existing institutional investors Prism Ventures, Charter Life Sciences and Ascent Biomedical Ventures. "We are pleased to close our Series B with Aperture as the lead. This financing will support our market introductions in the US and Europe. We are very fortunate to have top-tier investors supporting Xlumena's growth," stated Michael Allen, President and CEO of Xlumena.
About Xlumena, Inc.
Xlumena, Inc. is a privately-held interventional endoscopy-focused medical device company based in Mountain View, California. The Company has a number of advanced therapeutic devices in various stages of development, including the NAVIX Access Device (FDA-cleared) and the AXIOS Stent and Delivery System (CE marked). Formed in 2008 by Kenneth Binmoeller, MD (California Pacific Medical Center) and Michael Allen, Xlumena has raised $19M from venture capital sources to date.
For more information: http://xlumena.com
SOURCE Xlumena, Inc.